Microcap Ledger Elutia Inc. $ELUT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Silver Spring, MD
- Fiscal year end
- December 31
What the company doesAI summary of filing
Elutia Inc. develops and commercializes drug-eluting biomatrix products for surgical reconstruction and related applications. The company sells biologic matrix products including SimpliDerm (human acellular dermal matrix for soft tissue reconstruction) and cardiovascular repair products (ProxiCor, VasCure, and Tyke) through independent sales agents to U.S. healthcare facilities. The company is advancing its lead development programs, NXT-41 and NXT-41x, which are next-generation biologic scaffolds combined with local antibiotic delivery intended for reconstructive surgery applications; the company anticipates FDA clearance of NXT-41 in the second half of 2026 and NXT-41x by mid-2027. Elutia is revenue-generating from its commercial product portfolio and development-stage with respect to its pipeline programs. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $5.54M | −$15.12M | −$16.29M | $19.90M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $12.29M | $53.38M | −$44.81M | $36.35M | [10-K 2026-03-13] |
| FY ended Dec 2024 | $14.47M | −$53.95M | −$22.66M | $13.24M | [10-K 2026-03-13] |
- Quarterly cash burn
- −$8.15M
- Cash runway Estimate
- ~7.3 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2025-03-18; declared effective 2025-04-07 [S-3 2025-03-18]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-07] |
| 2026-01-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-02] |
| 2025-11-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-12] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-10 | Williams Michelle Leroux | exercise | 12,500 | — | [4 2026-09-14] |
| 2026-09-10 | Williams Michelle Leroux | other | 4,269 | $0.80 | [4 2026-09-14] |
| 2026-09-10 | Ferguson Matthew | exercise | 12,500 | — | [4 2026-09-14] |
| 2026-09-10 | Ferguson Matthew | other | 4,486 | $0.80 | [4 2026-09-14] |
| 2026-09-10 | Mills C Randal | exercise | 27,083 | — | [4 2026-09-14] |
| 2026-09-10 | Mills C Randal | other | 9,718 | $0.80 | [4 2026-09-14] |
| 2026-06-21 | Mills C Randal | exercise | 22,473 | — | [4 2026-06-22] |
| 2026-06-21 | Mills C Randal | other | 8,064 | $1.06 | [4 2026-06-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-21 | 8-K | Acquisition or disposition completed; Regulation FD disclosure |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-11 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 8-K | Listing notice or transfer |
| 2026-07-20 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-06-16 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-14 | 8-K | Results of operations |
| 2026-04-22 | DEF 14A | Proxy statement |
| 2026-03-13 | 10-K | Annual report |
Alerts for $ELUT
Email me when Elutia Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.